Amgen, Takeda deal

Takeda said it returned its Japanese rights to fulranumab ( AMG 403) and trebananib ( AMG 386) to Amgen. In 2008, Amgen granted exclusive, Japanese rights to Takeda for up to 13 compounds, including the two programs. The partners will continue to develop and commercialize the remaining compounds under the deal. ...